Intraperitoneal injection of DdBIC significantly reduced xenograft tumor growth in a dose-dependent manner (Fig. 7a), with GSDMC and OPA1 cleavage and eIF2α phosphorylation (Fig. 7b). Here, GSDMC is linked to neoplasm.